{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T13:15:03Z","timestamp":1788873303827,"version":"build-2803163510"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2013,4,10]],"date-time":"2013-04-10T00:00:00Z","timestamp":1365552000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neuropsychopharmacol"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1038\/npp.2013.85","type":"journal-article","created":{"date-parts":[[2013,4,10]],"date-time":"2013-04-10T15:37:24Z","timestamp":1365608244000},"page":"1921-1928","source":"Crossref","is-referenced-by-count":21,"title":["The Impact of Escitalopram on IL-2-Induced Neuroendocrine, Immune, and Behavioral Changes in Patients with Malignant Melanoma: Preliminary Findings"],"prefix":"10.1038","volume":"38","author":[{"given":"Dominique","family":"Musselman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica B","family":"Royster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa M","family":"Trimble","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara K","family":"Mann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel S","family":"Graciaa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcia D","family":"McNutt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N S Freda","family":"Auyeung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsay","family":"Oliver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David H","family":"Lawson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew H","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,4,10]]},"reference":[{"key":"BFnpp201385_CR1","unstructured":"American Psychiatric Association (1994) Diagnostic and Statistical Manual of Mental Disorders 4th edn. American Psychiatric Association: Washington, DC, USA."},{"key":"BFnpp201385_CR2","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/978-0-585-37970-8_12","volume":"461","author":"H Anisman","year":"1999","unstructured":"Anisman H, Merali Z (1999). Anhedonic and anxiogenic effects of cytokine exposure. Adv Exp Med Biol 461: 199\u2013233.","journal-title":"Adv Exp Med Biol"},{"key":"BFnpp201385_CR3","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/bjc.1983.15","volume":"47","author":"C Bindon","year":"1983","unstructured":"Bindon C, Czerniecki M, Ruell P, Edwards A, McCarthy WH, Harris R et al (1983). Clearance rates and systemic effects of intravenously administered interleukin 2 (IL-2) containing preparations in human subjects. Br J Cancer 47: 123\u2013133.","journal-title":"Br J Cancer"},{"key":"BFnpp201385_CR4","doi-asserted-by":"publisher","first-page":"445","DOI":"10.3109\/08923978909005379","volume":"11","author":"LD Butler","year":"1989","unstructured":"Butler LD, Mohler KM, Layman NK, Cain RL, Riedl PE, Puckett LD et al (1989). Interleukin-2 induced systemic toxicity: induction of mediators and immunopharmacologic intervention. Immunopharmacol Immunotoxicol 11: 445\u2013487.","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"BFnpp201385_CR5","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1200\/JCO.2000.18.10.2143","volume":"18","author":"L Capuron","year":"2000","unstructured":"Capuron L, Ravaud A, Dantzer R (2000). Early depressive symptoms in cancer patients receiving interleukin 2 and\/or interferon alfa-2b therapy. J Clin Oncol 18: 2143\u20132151.","journal-title":"J Clin Oncol"},{"key":"BFnpp201385_CR6","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1097\/00006842-200105000-00007","volume":"63","author":"L Capuron","year":"2001","unstructured":"Capuron L, Ravaud A, Dantzer R (2001). Timing and specificity of the cognitive changes induced by interleukin-2 and interferon-alpha treatments in cancer patients. Psychom Med 63: 376\u2013386.","journal-title":"Psychom Med"},{"key":"BFnpp201385_CR7","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1176\/appi.ajp.160.7.1342","volume":"160","author":"L Capuron","year":"2003","unstructured":"Capuron L, Raison CL, Musselman DL, Lawson DH, Nemeroff CB, Miller AH (2003). An exaggerated HPA axis response to the initial injection of interferon-alpha is associated with the development of depression during interferon-alpha therapy. Am J Psychiatry 160: 1342\u20131345.","journal-title":"Am J Psychiatry"},{"key":"BFnpp201385_CR8","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.4049\/jimmunol.139.7.2414","volume":"139","author":"JM Carlin","year":"1987","unstructured":"Carlin JM, Borden EC, Sondel PM, Byrne GI (1987). Biologic-response-modifier-induced indoleamine 2,3-dioxygenase activity in human peripheral blood mononuclear cell cultures. J Immunol 139: 2414\u20132418.","journal-title":"J Immunol"},{"key":"BFnpp201385_CR9","first-page":"251","volume":"9","author":"C Chambrier","year":"1990","unstructured":"Chambrier C, Mercatello A, Tognet E, Cottet-Emard JM, Cohen R, Blay JY et al (1990). Hormonal and metabolic effects of chronic interleukin-2 infusion in cancer patients. J Biol Response Modif 9: 251\u2013255.","journal-title":"J Biol Response Modif"},{"key":"BFnpp201385_CR10","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1210\/jcem-69-2-402","volume":"69","author":"KD Denicoff","year":"1987","unstructured":"Denicoff KD, Ribinow DR, Papa MZ, Simpson C, Seippp CA, Lotze MT et al (1987). The neuroendocrine effects of interleukin-2 treatment. J Clin Endocrinol Metab 69: 402\u2013410.","journal-title":"J Clin Endocrinol Metab"},{"key":"BFnpp201385_CR11","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1016\/j.biopsych.2007.05.026","volume":"62","author":"JC Felger","year":"2007","unstructured":"Felger JC, Alagbe O, Hu F, Mook D, Freeman AA, Sanchez MM et al (2007). Effects of interferon-alpha on rhesus monkeys: a non-human primate model of cytokine-induced depression. Biol Psychiatry 62: 1324\u20131333.","journal-title":"Biol Psychiatry"},{"key":"BFnpp201385_CR12","volume-title":"Structured Clinical Interview for DSM-IV Axis I Disorders SCID I: Clinician Version 2.0. Rev","author":"MB First","year":"1998","unstructured":"First MB, Spitzer RL, Gibbon M, Williams JBW (1998) Structured Clinical Interview for DSM-IV Axis I Disorders SCID I: Clinician Version 2.0. Rev. Biometrics Research Department, New York State Psychiatric Institute: New York, NY, USA."},{"key":"BFnpp201385_CR13","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","volume":"12","author":"MF Folstein","year":"1975","unstructured":"Folstein MF, Folstein SE, McHugh A (1975). \u201cMini-Mental State\u201d: a practical method for grading the cognitive state of patients for the clinician. J Psychiatric Res 12: 189\u2013198.","journal-title":"J Psychiatric Res"},{"key":"BFnpp201385_CR14","first-page":"572","volume":"69","author":"RD Gibbons","year":"2012","unstructured":"Gibbons RD, Hur K, Brown CH, Davis JM, Mann JJ (2012). Benefits from antidepressants: synthesis of 6-week patient-level outcomes from double-blind placebo-controlled randomized trials of fluoxetine and venlafaxine. Arch Gen Psychiatry 69: 572\u2013579.","journal-title":"Arch Gen Psychiatry"},{"key":"BFnpp201385_CR15","doi-asserted-by":"publisher","first-page":"5934","DOI":"10.4049\/jimmunol.169.10.5934","volume":"169","author":"E Goleva","year":"2002","unstructured":"Goleva E, Kisich KO, Leung DY (2002). A role for STAT5 in the pathogenesis of IL-2-induced glucocorticoid resistance. J Immunol 169: 5934\u20135940.","journal-title":"J Immunol"},{"key":"BFnpp201385_CR16","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1136\/jnnp.23.1.56","volume":"23","author":"M Hamilton","year":"1960","unstructured":"Hamilton M (1960). A rating scale for depression. J Neurol Neurosurg Psychiatry 23: 56\u201362.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"BFnpp201385_CR17","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1210\/endo.135.6.7988433","volume":"135","author":"UK Hanisch","year":"1994","unstructured":"Hanisch UK, Rowe W, Sharma S, Meaney MJ, Quirion R (1994). Hypothalamic-pituitary-adrenal activity during chronic central administration of interleukin-2. Endocrinology 135: 2465\u20132472.","journal-title":"Endocrinology"},{"key":"BFnpp201385_CR18","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/0006-8993(94)91799-X","volume":"650","author":"EW Hillhouse","year":"1994","unstructured":"Hillhouse EW (1994). Interleukin-2 stimulates the secretion of arginine vasopressin but not corticotropin-releasing hormone from rat hypothalamic cells in vitro. Brain Res 650: 323\u2013325.","journal-title":"Brain Res"},{"key":"BFnpp201385_CR19","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1067\/mai.2002.122465","volume":"109","author":"E Irusen","year":"2002","unstructured":"Irusen E, Matthews JG, Takahashi A, Barnes PJ, Chung KF, Adcock IM (2002). p38 Mitogen-activated protein kinase-induced glucocorticoid receptor phosphorylation reduces its activity: role in steroid-insensitive asthma. J Allergy Clin Immunol 109: 649\u2013657.","journal-title":"J Allergy Clin Immunol"},{"key":"BFnpp201385_CR20","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1159\/000014541","volume":"7","author":"C Jiang","year":"1998","unstructured":"Jiang C, Lu C (1998). Interleukin-2 and its effects in the central nervous system. Biol Signals Recept 7: 148\u2013156.","journal-title":"Biol Signals Recept"},{"key":"BFnpp201385_CR21","doi-asserted-by":"publisher","first-page":"2961","DOI":"10.1073\/pnas.88.7.2961","volume":"88","author":"S Karanth","year":"1991","unstructured":"Karanth S, McCann SM (1991). Anterior pituitary hormone control by interleukin-2. Proc Natl Acad Sci USA 88: 2961\u20132965.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFnpp201385_CR22","doi-asserted-by":"publisher","first-page":"2414","DOI":"10.1210\/endo.139.5.6005","volume":"129","author":"M Katahira","year":"1998","unstructured":"Katahira M, Iwasaki Y, Aoki Y, Oiso Y, Saito H (1998). Cytokine regulation of the rat proopiomelanocortin gene expression in AtT-20 cells. Endocrinology 129: 2414\u20132422.","journal-title":"Endocrinology"},{"key":"BFnpp201385_CR23","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1159\/000026457","volume":"8","author":"S Lacosta","year":"2000","unstructured":"Lacosta S, Merali Z, Anisman H (2000). Central monoamine activity following acute and repeated systemic interleukin-2 administration. Neuroimmunomodulation 8: 83\u201390.","journal-title":"Neuroimmunomodulation"},{"key":"BFnpp201385_CR24","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1192\/bjp.134.4.382","volume":"134","author":"S Montgomery","year":"1979","unstructured":"Montgomery S, Asberg M (1979). A new depression scale designed to be sensitive to change. Br J Psychiatry 134: 382\u2013389.","journal-title":"Br J Psychiatry"},{"key":"BFnpp201385_CR25","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1056\/NEJM200103293441303","volume":"344","author":"DL Musselman","year":"2001","unstructured":"Musselman DL, Lawson DH, Gumnick JF, Penna S, Goodkin R, Greiner K et al (2001). Paroxetine for the prevention of the depression and neurotoxicity induced by high dose interferon-alpha therapy. N Engl J Med 344: 961\u2013966.","journal-title":"N Engl J Med"},{"key":"BFnpp201385_CR26","unstructured":"National Institute for Clinical Excellence (2004) Depression: Management of Depression in Primary and Secondary Care. National Institute for Clinical Excellence: London, England."},{"key":"BFnpp201385_CR27","first-page":"120","volume":"2","author":"SE Nicolson","year":"2006","unstructured":"Nicolson SE, Miller AH, Lawson D, Musselman DL (2006). Neuropsychiatric effects of IL-2: mechanisms and treatment implications. Depression: Mind and Body 2: 120\u2013129.","journal-title":"Depression: Mind and Body"},{"key":"BFnpp201385_CR28","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/S0006-3223(00)01088-X","volume":"49","author":"CM Pariante","year":"2001","unstructured":"Pariante CM, Miller AH (2001). Glucocorticoid receptors in major depression: relevance to the pathophysiology and treatment. Biol Psychiatry 49: 391\u2013404.","journal-title":"Biol Psychiatry"},{"key":"BFnpp201385_CR29","first-page":"1522","volume":"76","author":"V Perraudin","year":"1993","unstructured":"Perraudin V, Delarue C, Lefebvre H, Contesse V, Kuhn JM, Vaudry H (1993). Vasopressin stimulates cortisol secretion from human adrenocortical tissue through activation of V1 receptors. J Clin Endocrinol Metab 76: 1522\u20131528.","journal-title":"J Clin Endocrinol Metab"},{"key":"BFnpp201385_CR30","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1046\/j.1365-2265.1999.00592.x","volume":"50","author":"C Raab","year":"1999","unstructured":"Raab C, Weidmann E, Schmidt A, Bregmann L, Badenhoop K, Usadel KH et al (1999). The effects of interleukin-2 treatment on endothelin and the activation of the hypothalamic-pituitary-adrenal axis. Clin Endocrinol (Oxf) 50: 37\u201344.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"BFnpp201385_CR31","doi-asserted-by":"publisher","first-page":"6187","DOI":"10.1523\/JNEUROSCI.14-10-06187.1994","volume":"14","author":"J Raber","year":"1994","unstructured":"Raber J, Bloom FE (1994). IL-2 induces vasopressin release from the hypothalamus and the amygdala: role of nitric oxide-mediated signaling. J Neurosci 14: 6187\u20136195.","journal-title":"J Neurosci"},{"key":"BFnpp201385_CR32","first-page":"815","volume":"272","author":"J Raber","year":"1995","unstructured":"Raber J, Koob GF, Bloom FE (1995). Interleukin-2 (IL-2) induces corticotropin-releasing factor (CRF) release from the amygdala and involves a nitric oxide-mediated signaling: comparison with the hypothalamic response. J Pharmacol Exp Ther 272: 815\u2013824.","journal-title":"J Pharmacol Exp Ther"},{"key":"BFnpp201385_CR33","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1038\/mp.2009.116","volume":"15","author":"CL Raison","year":"2010","unstructured":"Raison CL, Dantzer D, Kelley KW, Lawson MC, Woolwine BJ, Vogt G et al (2010). CSF concentrations of brain tryptophan and kynurenines during immune stimulation with IFN-alpha: relationship to CNS immune responses and depression. Mol Psychiatry 15: 393\u2013403.","journal-title":"Mol Psychiatry"},{"key":"BFnpp201385_CR34","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1176\/appi.ajp.160.9.1554","volume":"160","author":"CL Raison","year":"2003","unstructured":"Raison CL, Miller AH (2003a). When not enough is too much: the role of insufficient glucocorticoid signaling in the pathophysiology of stress-related disorders. Am J Psychiatry 160: 1554\u20131565.","journal-title":"Am J Psychiatry"},{"key":"BFnpp201385_CR35","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/S0006-3223(03)00413-X","volume":"54","author":"CL Raison","year":"2003","unstructured":"Raison CL, Miller AH (2003b). Depression in cancer: new developments regarding diagnosis and treatment. Biol Psychiatry 54: 283\u2013294.","journal-title":"Biol Psychiatry"},{"key":"BFnpp201385_CR36","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1097\/00000658-198910000-00008","volume":"210","author":"SA Rosenberg","year":"1989","unstructured":"Rosenberg SA, Lotze MT, Yang JC, Aebersold PM, Linehan WM, Seipp CA et al (1989). Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg 210: 474\u2013485.","journal-title":"Ann Surg"},{"key":"BFnpp201385_CR37","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1038\/bjc.1993.96","volume":"67","author":"KA Saraya","year":"1993","unstructured":"Saraya KA, Balkwill FR (1993). Temporal sequence and cellular origin of interleukin-2 stimulated cytokine gene expression. Br J Cancer 67: 514\u2013521.","journal-title":"Br J Cancer"},{"key":"BFnpp201385_CR38","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4899-1277-0","volume-title":"Sourcebook of Adult Assessment Strategies","author":"NS Schutte","year":"1995","unstructured":"Schutte NS, Malouff JM (1995) Sourcebook of Adult Assessment Strategies. Plenum Press: New York, NY, USA."},{"key":"BFnpp201385_CR39","doi-asserted-by":"publisher","first-page":"2429","DOI":"10.1002\/sim.1519","volume":"22","author":"J Shao","year":"2003","unstructured":"Shao J, Zhang B (2003). Last observation carry-forward and last observation analysis. Stat Med 22: 2429\u20132441.","journal-title":"Stat Med"},{"key":"BFnpp201385_CR40","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1200\/JCO.1992.10.7.1119","volume":"10","author":"DT Sleijfer","year":"1992","unstructured":"Sleijfer DT, Janssen RA, Buter J, de Vries EG, Willemse PH, Mulder NH (1992). Phase II study of subcutaneous interleukin-2 in unselected patients with advanced renal cell cancer on an outpatient basis. J Clin Oncol 10: 1119\u20131123.","journal-title":"J Clin Oncol"},{"key":"BFnpp201385_CR41","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1016\/S0028-3908(02)00298-8","volume":"43","author":"P Song","year":"2002","unstructured":"Song P, Lie-Cheng W, Wang GD, Zhou Z, Zhao ZQ (2002). Interleukin-2 regulates membrane potentials and calcium channels via mu opioid receptors in rat dorsal root ganglion neurons. Neuropharmacology 43: 1324\u20131329.","journal-title":"Neuropharmacology"},{"key":"BFnpp201385_CR42","first-page":"163","volume":"19","author":"MP Spina","year":"1994","unstructured":"Spina MP, Santi G, Poggiato M, Bacchioni G, Sacca G, Cerri A et al (1994). In vitro effects of IL-2 on human hypophyseal adenoma. Minerva Endocrinol 19: 163\u2013168.","journal-title":"Minerva Endocrinol"},{"key":"BFnpp201385_CR43","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1177\/030089169107700609","volume":"77","author":"S Spinazz\u00e9","year":"1991","unstructured":"Spinazz\u00e9 S, Viviani S, Bidoli P, Rovelli F, Palmer P, Franks CR et al (1991). Effect of prolonged subcutaneous administration of interleukin-2 on the circadian rhythms of cortisol and beta-endorphin in advanced small cell lung cancer patients. Tumori 77: 496\u2013499.","journal-title":"Tumori"},{"key":"BFnpp201385_CR44","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1046\/j.1365-2265.2003.01803.x","volume":"59","author":"O Witzke","year":"2003","unstructured":"Witzke O, Winterhagen T, Kribben A, Philipp T, Mann K, Reinhardt W (2003). Interleukin-2 given to asymptomatic HIV-infected individuals leads to an exaggerated response of the pituitary gland to the action of CRH. Clin Endocrinol 59: 104\u2013109.","journal-title":"Clin Endocrinol"}],"container-title":["Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/npp201385.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/npp201385","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/npp201385.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T23:04:22Z","timestamp":1688166262000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/npp201385"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4,10]]},"references-count":44,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["BFnpp201385"],"URL":"https:\/\/doi.org\/10.1038\/npp.2013.85","relation":{},"ISSN":["0893-133X","1740-634X"],"issn-type":[{"value":"0893-133X","type":"print"},{"value":"1740-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,4,10]]}}}